Replies to post #328737 on Amarin Corp Plc (AMRN)

[HDGabor]

P-

pharmacy could do a generic switch without physician’s approval and patient getting worthless fake substitute without physician knowing until follow-up visit

My understanding of the method: pharmacy could do a generic switch without physician’s approval and patient getting worthless fake substitute WITHOUT coverage, aka for (e.g.) $200+ / script ... I do not think it is a threat.

Best,
G

ps.:

worthless fake

What is the basis of this? (Top of your emotion.)

[ralphey]

The pharmacy will then be liable for infringement - and therein lies the war of attrition AMRN will need to fight - the problem is no one knows for what indication an MD writes the RX for - thereby allowing infringement to slip in and requiring a lengthy, messy, time consuming and expensive process to eliminate such BUT WAIT ...ALL IS NOT LOST ...ENTER

VASTOR - the new enhanced statin (VAscepa plus a statin) - its clear that it must be for CAD and will be impossible to substitute gV for such without revealing direct infringement -

1.) VASTOR is much easier to market Docs know what a statin is and will be immediately attracted to an ENHANCED STATIN OVER A MODIFIED FISH OIL
2.) Infringement is immediately proven preventing such
3.) AMRN captures vast majority of statin market
4.) Stock price soars